A North Dakota overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
36.8% of North Dakota adults had obesity in 2024 (CDC BRFSS) 3, up steadily from 35.2% in 2021, 35.4% in 2022, and 35.6% in 2023 3. Fargo, the state's largest city and this hub's child page, sits somewhat lower: 34.3% crude adult obesity prevalence (35.8% age-adjusted) on 2023 BRFSS data via the CDC PLACES 2025 release 4.
North Dakota's population is 796,568 (Census Vintage 2024) 5; Fargo's is 136,285 6.
North Dakota Medicaid does not cover GLP-1 medications for standalone or general obesity. The program's Preferred Drug List (Version 2026.6, effective July 31, 2026) allows only four drugs — phentermine, bupropion, naltrexone, and topiramate — without prior authorization under the "Weight Loss" (Obesity) indication. Semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) are excluded from that list outright 1.
GLP-1 coverage exists only through three narrow, specialist-gated prior-authorization pathways tied to specific comorbidities — never to obesity alone: (1) cardiovascular risk reduction for non-diabetic patients aged 55–74 with BMI 27–<35 and a prior heart attack, or a prior stroke plus peripheral artery disease; (2) MASH/NASH liver disease with a specialist-confirmed fibrosis stage (biopsy, Fibroscan, ELF, MRI-PDFF, or MRE); and (3) obstructive sleep apnea, Zepbound only, requiring sign-off from a sleep specialist plus a documented 6-month failed CPAP trial and a prior 6-month weight-management pharmacotherapy trial 1.
A fourth, unrelated pathway — Ozempic injection or Victoza without PA — exists only for antipsychotic-induced weight gain (ICD-10 T43.505A/D/S), not weight loss on its own. Standard Type 2 diabetes coverage (Ozempic, Rybelsus, Victoza preferred; Mounjaro and Trulicity with PA) is a separate pathway tied to a diabetes diagnosis, not to obesity 12.
Astra's price in North Dakota is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no North Dakota-specific price, surcharge, or discount.
Verified local clinic pricing for the North Dakota market is compiled on the Fargo city page, not here. For household context, median household income is $77,871 (± $2,755 margin of error, ACS 2024 1-year) 7, and roughly 6.1% of residents — about 47,118 of 777,259 — are uninsured, derived from ACS 2024 1-year table B27001 with all age/sex categories summed 8.
North Dakota Board of Medicine. TODO — verify and cite the Board's specific telehealth-prescribing rules for GLP-1s (live-video requirement, initial in-person exam rule, any controlled-substance carve-outs) before this section ships as final. This research pass could not confirm those specifics from a primary source, so no rule and no board URL are published here.
HRSA HPSA designation counts for North Dakota could not be verified: data.hrsa.gov's Socrata/API endpoints returned HTTP 403 (Akamai bot-block) on every automated access attempt, and the HPSA Find tool page returned only tool documentation rather than live North Dakota statistics. That is a genuine gap, not a guess, and it needs a follow-up with interactive access to data.hrsa.gov's shortage-area tool before any shortage-area count appears on this page.
Astra is licensed to treat patients in all 50 states, North Dakota included — Fargo and the rest of the state alike.
Astra treats patients in North Dakota through state-licensed physicians.
Fargo is North Dakota's city page under this hub.
No — not for general obesity. North Dakota Medicaid's Preferred Drug List (v2026.6, effective July 31, 2026) covers only phentermine, bupropion, naltrexone, and topiramate without prior authorization under the "Weight Loss" indication. GLP-1s are covered only through narrow, specialist-gated prior authorizations for specific comorbidities — cardiovascular risk reduction, MASH/NASH liver disease, or obstructive sleep apnea (Zepbound only) — never for weight loss alone.
No. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide (12-month plans, $816/$1,416 billed annually) in every state it serves, including North Dakota. There is no state-specific pricing, markup, or discount.
36.8% of North Dakota adults had obesity as of 2024, per the CDC's Behavioral Risk Factor Surveillance System — up from 35.2% in 2021. Fargo's separately measured rate (CDC PLACES, 2023 data) was 34.3%.
Yes. Astra is licensed and available in all 50 states, including North Dakota.
Prescribing is governed by the North Dakota Board of Medicine. [TODO: this answer needs the board's specific telehealth-prescribing rules for GLP-1s, verified from a primary source — not yet confirmed in this research pass.]
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.